Respiratory Medicine · Nov 18, 2026

Prospective Real-World Evaluation of Empagliflozin on Pulmonary Function and Exercise Capacity in Patients with Type 2 Diabetes and COPD

By Memarian M, Mahdavi M, Bitaraf M et al.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) frequently coexist and are associated with increased morbidity, systemic inflammation, impaired exercise capacity, and reduced quality of life. Beyond glycemic control, empagliflozin has demonstrated anti-inflammatory and metabolic benefits that may potentially improve respiratory outcomes. This study aimed to evaluate the effects of empagliflozin on pulmonary function, inflammatory markers, exercise capacity, and COPD-related symptoms in patients with coexisting COPD and T2DM. METHODS: A prospective, single-arm, before-and-after interventional study was conducted in 31 patients with coexisting COPD and type 2 diabetes mellitus. Participants received empagliflozin (10 mg/day) for three months in addition to their stable antidiabetic therapy. Pulmonary function, inflammatory markers, oxygen saturation, six-minute walk distance, COPD Assessment Test (CAT) score, body weight, and HbA1c were evaluated at baseline and after treatment. Changes in outcome measures were compared between the two time points. RESULTS: After three months of treatment, significant improvements were observed in FEV1 (P < 0.001) and MMEF (P = 0.019), whereas the change in FEV1/FVC ratio was not statistically significant (P = 0.106). CRP levels decreased significantly (P = 0.007), while ESR showed a non-significant reduction (P = 0.108). Significant improvements were also observed in SpO₂ (P = 0.033), six-minute walk distance (P < 0.001), and CAT score (P < 0.001). Furthermore, empagliflozin significantly reduced body weight (P < 0.001) and HbA1c levels (P = 0.004). CONCLUSION: Empagliflozin therapy was associated with significant improvements in pulmonary function, exercise capacity, COPD symptom burden, inflammatory status, glycemic control, and body weight in patients with coexisting COPD and T2DM. These findings suggest that empagliflozin may provide clinically relevant benefits beyond glucose lowering and could represent a promising therapeutic option in this patient population. Larger controlled studies are needed to confirm these findings.

doi.org/10.1016/j.rmed.2026.109309PubMed 43051472Interventions

AgingResearch.News